Amendments to the Specification

Please insert the following new header and paragraph on page 1, immediately following the title:

--CROSS REFERENCE TO RELATED APPLICATIONS

This is a divisional of U.S. Application No. 09/719,243, filed March 19, 2001, which was the U.S. National Stage of International Application No. PCT/US99/12309, filed June 3, 1999, which in turn claims the benefit of U.S. Provisional Application No. 60/088,813, filed June 10, 1998.--

Replace the paragraphs on page 6, lines 22-27 with the following rewritten paragraphs:

-- FIGS. 7a-7c are graphs is a graph illustrating the stabilization of cell-surface HLA-A1 (a), -A2 (b), and -A3 (c) by mutant $h\beta_2m$ and peptide. All values are expressed as mean fluorescence intensity.

FIGS. 8a-8c are graphs showing shows the inhibition of myc-β_2m binding by S55V and $h\beta_2m$ to cell-surface HLA-A1 (a), -A2 (b), and -A3 (c). All values are expressed as mean fluorescence intensity.

FIGS. 9a-9b are graphs illustrating illustrates that the S55V mutant enhances CTL recognition better than wild-type $h\beta_2m$ in both Hmy2.C1R-A2 (a) and Hmy2.C1R-A3 (b) target cells.--

Replace the paragraph on page 6, line 33 - page 7, line 4, with the following rewritten paragraph:

β_2m: beta-2 microglobulin. This term encompasses any mammalian beta-2 microglobulin protein, including human and murine beta-2 microglobulins. The term "$h\beta_2m$" refers specifically to human beta-2 microglobulin. cDNAs and genes encoding mammalian $\beta_2$ms are well known in the art, as are the corresponding β_2m protein sequences. Examples include those sequences described in: Parnes and Seidman (*Cell* 29:661-9, 1982), Gates et al. (*Proc. Natl. Acad. Sci. USA* 78:554-8, 1981) (murine); Suggs et al. (*Proc. Natl. Acad. Sci. USA*

78:6613-7, 1981), Guessow et al. (*J. Immunol.* 139:3132-8, 1987), Cunningham et al. (*Biochem.* 12:4811-22, 1973) (human); and Ellis et al. (*Immunogenetics* 38:310, 1993) (bovine). These sequences are also available on the Internet at GenBank's website at http://www.ncbi.nlm.nih.gov/Entrez/index.html.

On page 27, include the enclosed abstract (which is submitted on a separate sheet) as page 27 of the present application.

Replace pages 1-8 of the sequence listing with the enclosed sequence listing (8 pages).